Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma

被引：0
|
作者：
Zhao, Jessie [1 ,2 ]
Khong, Tiffany T. [1 ,2 ]
Gorniak, Malgorzata [3 ]
Khaled, Abir [4 ]
McDonald, Zac [4 ]
Reynolds, John [1 ,2 ]
Wong, Daniel [1 ,2 ]
Bingham, Nicholas [1 ,2 ]
Johnston, Anna M. [5 ]
Motorna, Olga [6 ]
Murphy, Nicholas E. [5 ]
Quach, Hang [7 ]
Yang, Liqiang [4 ]
Spencer, Andrew [1 ,2 ]
机构：
[1] Alfred Hosp, Dept Malignant Haematol & Stem Cell Transplantat, Melbourne, Vic, Australia
[2] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia
[3] Alfred Hosp, Alfred Pathol, Melbourne, Vic, Australia
[4] Rapid Novor, Kitchener, ON, Canada
[5] Royal Hobart Hosp, Hobart, Tas, Australia
[6] Eastern Hlth, Melbourne, Vic, Australia
[7] St Vincents Hosp Melbourne, East Melbourne, Australia
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-179742
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Multiple myeloma, immunotherapy and minimal residual disease
    Kusenda, J.
    Kovarikova, A.
    NEOPLASMA, 2016, 63 (05) : 651 - 658
  • [42] Minimal residual disease monitoring in multiple myeloma
    Davies, FE
    Rawstron, RC
    Owen, RG
    Morgan, GJ
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) : 197 - 222
  • [43] Standardisation of minimal residual disease in multiple myeloma
    Innao, V.
    Allegra, A.
    Russo, S.
    Gerace, D.
    Vaddinelli, D.
    Alonci, A.
    Allegra, A. G.
    Musolino, C.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [44] Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients
    Noori, Somayya
    Wijnands, Charissa
    Bonifay, Vincent
    Luider, Theo
    Sonigo, Pierre
    Dejoie, Thomas
    Gloerich, Jolein
    van Gool, Alain
    van Duijn, Martijn
    Jacobs, Joannes
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S75 - S75
  • [45] Monitoring Minimal Residual Disease in Patients with Multiple Myeloma By Tracking Serum M-Protein Using Mass Spectrometry
    Fan, Huishou
    Wang, Bing
    Qiu, Lugui
    Ma, Bin
    An, Gang
    BLOOD, 2023, 142
  • [46] Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow
    Zajec, Marina
    Langerhorst, Pieter
    Noori, Somayya
    van Duijn, Martijn
    de Rijke, Yolanda
    Gloerich, Jolein
    van Gool, Alain
    Corre, Jill
    Dejoie, Thomas
    Caillon, Helene
    Jacobs, Joannes
    Luider, Theo
    Avet-Loiseau, Herve
    BLOOD, 2020, 136
  • [47] New criteria for response assessment: role of minimal residual disease in multiple myeloma
    Paiva, Bruno
    van Dongen, Jacques J. M.
    Orfao, Alberto
    BLOOD, 2015, 125 (20) : 3059 - 3068
  • [48] RESPONSE ASSESSMENT IN MULTIPLE MYELOMA: CLINICAL SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING
    Paiva, Bruno
    Vidriales, Maria-Belen
    Montalban, Maria-Angeles
    Blade, Joan
    Lahuerta, Juan-Jose
    Orfao, Alberto
    San Miguel, Jesus F.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2011, 80B (06) : 390 - 390
  • [49] Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
    Jamet, Bastien
    Zamagni, Elena
    Nanni, Cristina
    Bailly, Clement
    Carlier, Thomas
    Touzeau, Cyrille
    Michaud, Anne-Victoire
    Moreau, Philippe
    Bodet-Milin, Caroline
    Kraeber-Bodere, Francoise
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) : 1 - 14
  • [50] Functional and psychological impact of minimal residual disease assessment on patients with multiple myeloma
    Correia, Nuno
    Dowling, Emma
    Popat, Rakesh
    Rabin, Neil
    Kyriakou, Chara
    Sive, Jonathan
    Yong, Kwee
    Wechalekar, Ashutosh
    BRITISH JOURNAL OF HAEMATOLOGY, 2023,
12345